Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.16
MYL's Cash to Debt is ranked lower than
89% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. MYL: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
MYL' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.79 Max: 44.56
Current: 0.16
0.02
44.56
Equity to Asset 0.45
MYL's Equity to Asset is ranked lower than
74% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MYL: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
MYL' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.46 Max: 0.9
Current: 0.45
0.19
0.9
Interest Coverage 4.26
MYL's Interest Coverage is ranked lower than
77% of the 475 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.69 vs. MYL: 4.26 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.61 Max: 9.19
Current: 4.26
0.83
9.19
F-Score: 5
Z-Score: 2.19
M-Score: -2.47
WACC vs ROIC
9.62%
7.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.43
MYL's Operating margin (%) is ranked higher than
69% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. MYL: 14.43 )
Ranked among companies with meaningful Operating margin (%) only.
MYL' s Operating margin (%) Range Over the Past 10 Years
Min: 5.8  Med: 16.36 Max: 26.53
Current: 14.43
5.8
26.53
Net-margin (%) 8.26
MYL's Net-margin (%) is ranked higher than
58% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. MYL: 8.26 )
Ranked among companies with meaningful Net-margin (%) only.
MYL' s Net-margin (%) Range Over the Past 10 Years
Min: -3.53  Med: 9.01 Max: 14.68
Current: 8.26
-3.53
14.68
ROE (%) 8.30
MYL's ROE (%) is ranked higher than
55% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. MYL: 8.30 )
Ranked among companies with meaningful ROE (%) only.
MYL' s ROE (%) Range Over the Past 10 Years
Min: -14.72  Med: 14.57 Max: 29.99
Current: 8.3
-14.72
29.99
ROA (%) 3.62
MYL's ROA (%) is ranked higher than
50% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. MYL: 3.62 )
Ranked among companies with meaningful ROA (%) only.
MYL' s ROA (%) Range Over the Past 10 Years
Min: -2.47  Med: 4.61 Max: 9.21
Current: 3.62
-2.47
9.21
ROC (Joel Greenblatt) (%) 22.66
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. MYL: 22.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.9  Med: 31.19 Max: 47.2
Current: 22.66
17.9
47.2
Revenue Growth (3Y)(%) 5.40
MYL's Revenue Growth (3Y)(%) is ranked lower than
51% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. MYL: 5.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.1  Med: 15.20 Max: 54.5
Current: 5.4
-6.1
54.5
EBITDA Growth (3Y)(%) 5.20
MYL's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. MYL: 5.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.4  Med: 11.20 Max: 107.9
Current: 5.2
-20.4
107.9
EPS Growth (3Y)(%) 3.80
MYL's EPS Growth (3Y)(%) is ranked lower than
56% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. MYL: 3.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.1  Med: 3.80 Max: 110.4
Current: 3.8
-29.1
110.4
» MYL's 10-Y Financials

Financials (Next Earnings Date: 2016-08-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MYL Guru Trades in Q2 2015

Larry Robbins 1,815,874 sh (New)
David Tepper 989,528 sh (New)
Louis Moore Bacon 210,000 sh (New)
Eric Mindich 1,456,404 sh (New)
Jim Simons 548,006 sh (New)
John Keeley 37,050 sh (New)
Kyle Bass 780,251 sh (New)
Steven Cohen 1,331,200 sh (+425.54%)
Mario Gabelli 33,250 sh (+232.50%)
John Paulson 21,913,061 sh (+46.59%)
George Soros 160,000 sh (unchged)
Tom Russo 5,850 sh (unchged)
Vanguard Health Care Fund 15,891,898 sh (unchged)
Joel Greenblatt Sold Out
First Eagle Investment Sold Out
Scott Black 185,573 sh (-1.06%)
Pioneer Investments 631,760 sh (-23.54%)
Paul Tudor Jones 12,766 sh (-88.34%)
» More
Q3 2015

MYL Guru Trades in Q3 2015

Jim Simons 1,716,741 sh (+213.27%)
Mario Gabelli 67,250 sh (+102.26%)
John Keeley 56,120 sh (+51.47%)
Vanguard Health Care Fund 23,262,875 sh (+46.38%)
Steven Cohen 1,000,000 sh (unchged)
Tom Russo 5,850 sh (unchged)
John Paulson 21,913,061 sh (unchged)
Eric Mindich Sold Out
Scott Black 180,575 sh (-2.69%)
Paul Tudor Jones 10,768 sh (-15.65%)
Pioneer Investments 365,302 sh (-42.18%)
Larry Robbins 934,006 sh (-48.56%)
David Tepper 470,071 sh (-52.50%)
Louis Moore Bacon 80,000 sh (-61.90%)
Steven Cohen 360,900 sh (-72.89%)
Kyle Bass 78,905 sh (-89.89%)
» More
Q4 2015

MYL Guru Trades in Q4 2015

David Einhorn 2,890,000 sh (New)
Joel Greenblatt 9,029 sh (New)
David Tepper 853,749 sh (+81.62%)
Pioneer Investments 469,785 sh (+28.60%)
Vanguard Health Care Fund 24,253,075 sh (+4.26%)
John Paulson 22,794,061 sh (+4.02%)
Tom Russo 5,850 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Samuel Isaly 548,000 sh (unchged)
Kyle Bass Sold Out
Larry Robbins Sold Out
Jim Simons Sold Out
John Keeley 51,580 sh (-8.09%)
Paul Tudor Jones 8,100 sh (-24.78%)
Louis Moore Bacon 38,678 sh (-51.65%)
Mario Gabelli 26,450 sh (-60.67%)
Scott Black 48,980 sh (-72.88%)
Steven Cohen 100 sh (-99.97%)
» More
Q1 2016

MYL Guru Trades in Q1 2016

Joel Greenblatt 837,728 sh (+9178.19%)
Vanguard Health Care Fund 26,679,385 sh (+10.00%)
John Paulson 23,335,861 sh (+2.38%)
John Paulson 611,200 sh (unchged)
David Einhorn 2,890,000 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
John Keeley Sold Out
David Tepper Sold Out
Samuel Isaly Sold Out
Tom Russo 5,395 sh (-7.78%)
Scott Black 42,509 sh (-13.21%)
Paul Tudor Jones 6,455 sh (-20.31%)
Mario Gabelli 17,000 sh (-35.73%)
Pioneer Investments 54,144 sh (-88.47%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:ZTS, OTCPK:SGIOY, OTCPK:ESALY, OTCPK:MKGAY, NYSE:PRGO, OTCPK:TKPYY, OTCPK:APNHY, OTCPK:MTZPY, OTCPK:HLUYY, NYSE:VRX, NYSE:RDY, NYSE:MNK, OTCPK:MDABY, NYSE:TARO, NAS:OPK, OTCPK:HYPMY, OTCPK:IPSEY, NAS:NBIX, NAS:AKRX, NAS:ENDP » details
Traded in other countries:6MY.Germany, MYL1.Switzerland, 0R5P.UK,
Mylan NV together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Mylan NV was incorporated in Netherlands on July 7, 2014. The Company along with its subsidiaries is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. It also operates a research and development network that delivers a robust product pipeline. The Company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as active pharmaceutical ingredients. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Specialty segment engages in the development and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and has also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.

Guru Investment Theses on Mylan NV

John Keeley Comments on Mylan Labs - Apr 26, 2016

Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Keeley Funds Comments on Mylan N.V. - Feb 03, 2016

The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis.



From the Keeley All Cap Value Fund 4th quarter 2015 shareholder letter.



Check out John Keeley latest stock trades

David Einhorn Comments on Mylan - Jan 19, 2016

We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant.

We acknowledge eventual headwinds for the company’s branded EpiPen product, whichcould encounter competition from generics in late 2016. However, we see medium-termupside from a competitor recall, an announced share repurchase, and board review ofcorporate governance complaints. Ultimately, we expect MYL to earn close to $7 per share in2018, driven by a robust pipeline of respiratory, injectable and biologic drugs and by furthercapital deployment including share repurchases. We initiated our position at an average priceof $45.32, about 9x 2016 consensus EPS estimates. MYL shares ended the quarter at $54.07.

From David Einhorn (Trades, Portfolio)'s Green Light Capital fourth quarter 2015 shareholder letter.

Check out David Einhorn latest stock trades

Keeley Funds Comments on Mylan NV - Nov 03, 2015

The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative impact on the entire industry.





From the Keeley All-Cap Value Fund commentary on third quarter 2015.



Check out John Keeley latest stock trades

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Samuel Isaly Trades in Health Care Stocks in 1st Quarter Guru sells stakes in Health Net, Mylan, trims stake in Bristol-Myers Squibb
Samuel Isaly (Trades, Portfolio), manager of Eaton Vance Worldwide Health Sciences Fund, was an active investor in health care-related stocks long before government became involved in the sector. His transactions in the first quarter, ended Feb. 29, reflected that interest. Read more...
John Keeley Comments on Mylan Labs Guru stock highlight
Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position. Read more...
Keeley Funds Comments on Mylan N.V. Guru stock highlight
The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis. Read more...
David Einhorn Comments on Mylan Guru stock highlight
We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant. Read more...
Vanguard Raises Stakes in Biogen, Mylan, Merck Fund buys no new stakes in 3rd quarter
As its name suggests, Vanguard Health Care Fund (Trades, Portfolio) is almost exclusively interested in health care companies. It bought no new stakes in the third quarter, but it did make additions to several existing stakes. Read more...
Keeley Funds Comments on Mylan NV Guru stock highlight.
The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative Read more...
Alan Fournier Sells Nine Stakes in Second Quarter Divestitures are the most Fournier has recorded in years
Alan Fournier (Trades, Portfolio) founded Pennant Capital Management in 2001 and manages Pennant Master Fund, Pennant Windward Master Fund, Broadway Gate Master Fund Ltd.,and Pennant General Partner LLC. Today Pennant Capital Management is worth around $4 billion. Read more...
Sequoia Fund Comments on Perrigo Guru stock highlight
Saatvik Agarwal: Read more...
Kyle Bass Focuses on Fuel, Pharmaceutical Stocks in Second Quarter
If there was a theme to Kyle Bass (Trades, Portfolio)’ investment activity in the second quarter, the founder of Dallas-based Hayman Capital Management L.P., displayed an interest in fuel and pharmaceutical stocks. Not all of Bass’ transactions fit neatly into that category, of course, but many did, including most of the largest ones. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 30.01
MYL's P/E(ttm) is ranked lower than
53% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.41 vs. MYL: 30.01 )
Ranked among companies with meaningful P/E(ttm) only.
MYL' s P/E(ttm) Range Over the Past 10 Years
Min: 7.32  Med: 25.43 Max: 112.56
Current: 30.01
7.32
112.56
Forward P/E 9.49
MYL's Forward P/E is ranked higher than
84% of the 81 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. MYL: 9.49 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.01
MYL's PE(NRI) is ranked lower than
52% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.39 vs. MYL: 30.01 )
Ranked among companies with meaningful PE(NRI) only.
MYL' s PE(NRI) Range Over the Past 10 Years
Min: 7.32  Med: 25.43 Max: 112.56
Current: 30.01
7.32
112.56
Price/Owner Earnings (ttm) 38.71
MYL's Price/Owner Earnings (ttm) is ranked lower than
55% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.57 vs. MYL: 38.71 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MYL' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.15  Med: 35.23 Max: 5766.67
Current: 38.71
13.15
5766.67
P/B 2.26
MYL's P/B is ranked higher than
60% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. MYL: 2.26 )
Ranked among companies with meaningful P/B only.
MYL' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 2.66 Max: 7.02
Current: 2.26
0.64
7.02
P/S 2.47
MYL's P/S is ranked higher than
54% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. MYL: 2.47 )
Ranked among companies with meaningful P/S only.
MYL' s P/S Range Over the Past 10 Years
Min: 0.41  Med: 1.83 Max: 4.71
Current: 2.47
0.41
4.71
PFCF 16.34
MYL's PFCF is ranked higher than
67% of the 221 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.52 vs. MYL: 16.34 )
Ranked among companies with meaningful PFCF only.
MYL' s PFCF Range Over the Past 10 Years
Min: 8.82  Med: 19.08 Max: 47.85
Current: 16.34
8.82
47.85
POCF 13.08
MYL's POCF is ranked higher than
64% of the 292 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.35 vs. MYL: 13.08 )
Ranked among companies with meaningful POCF only.
MYL' s POCF Range Over the Past 10 Years
Min: 6.13  Med: 12.42 Max: 40.9
Current: 13.08
6.13
40.9
EV-to-EBIT 24.99
MYL's EV-to-EBIT is ranked lower than
60% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.71 vs. MYL: 24.99 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 17.95 Max: 36.9
Current: 24.99
-10.7
36.9
EV-to-EBITDA 12.77
MYL's EV-to-EBITDA is ranked higher than
65% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. MYL: 12.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: 11.00 Max: 23.3
Current: 12.77
-17.7
23.3
PEG 4.04
MYL's PEG is ranked lower than
71% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.01 vs. MYL: 4.04 )
Ranked among companies with meaningful PEG only.
MYL' s PEG Range Over the Past 10 Years
Min: 0.74  Med: 2.66 Max: 6.47
Current: 4.04
0.74
6.47
Shiller P/E 90.76
MYL's Shiller P/E is ranked lower than
70% of the 151 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 50.39 vs. MYL: 90.76 )
Ranked among companies with meaningful Shiller P/E only.
MYL' s Shiller P/E Range Over the Past 10 Years
Min: 14.48  Med: 81.75 Max: 173.66
Current: 90.76
14.48
173.66
Current Ratio 1.67
MYL's Current Ratio is ranked lower than
67% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MYL: 1.67 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 3.12 Max: 8.49
Current: 1.67
1.21
8.49
Quick Ratio 1.13
MYL's Quick Ratio is ranked lower than
70% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. MYL: 1.13 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.58 Max: 6.76
Current: 1.13
0.85
6.76
Days Inventory 132.22
MYL's Days Inventory is ranked lower than
61% of the 666 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. MYL: 132.22 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 136.05 Max: 168.24
Current: 132.22
88.95
168.24
Days Sales Outstanding 96.87
MYL's Days Sales Outstanding is ranked lower than
66% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. MYL: 96.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.32  Med: 84.21 Max: 107.26
Current: 96.87
70.32
107.26
Days Payable 72.00
MYL's Days Payable is ranked higher than
52% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.26 vs. MYL: 72.00 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 44.56  Med: 72.50 Max: 101.21
Current: 72
44.56
101.21

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.41
MYL's Price/Projected FCF is ranked higher than
76% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. MYL: 1.41 )
Ranked among companies with meaningful Price/Projected FCF only.
MYL' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.40 Max: 2.5
Current: 1.41
0.62
2.5
Price/DCF (Earnings Based) 2.80
MYL's Price/DCF (Earnings Based) is ranked lower than
86% of the 80 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.31 vs. MYL: 2.80 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.34
MYL's Price/Median PS Value is ranked lower than
62% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. MYL: 1.34 )
Ranked among companies with meaningful Price/Median PS Value only.
MYL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 1.88 Max: 3.47
Current: 1.34
0.36
3.47
Price/Peter Lynch Fair Value 3.33
MYL's Price/Peter Lynch Fair Value is ranked lower than
80% of the 173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. MYL: 3.33 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYL' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.67  Med: 1.93 Max: 10.2
Current: 3.33
0.67
10.2
Earnings Yield (Greenblatt) (%) 4.04
MYL's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MYL: 4.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.7  Med: 5.30 Max: 19
Current: 4.04
2.7
19
Forward Rate of Return (Yacktman) (%) 12.81
MYL's Forward Rate of Return (Yacktman) (%) is ranked higher than
60% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. MYL: 12.81 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.7  Med: 14.70 Max: 28.4
Current: 12.81
7.7
28.4

More Statistics

Revenue (TTM) (Mil) $9,749
EPS (TTM) $ 1.56
Beta1.32
Short Percentage of Float6.51%
52-Week Range $37.59 - 58.05
Shares Outstanding (Mil)508.34

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 10,909 12,843 13,635
EPS ($) 4.84 5.61 6.37
EPS w/o NRI ($) 4.84 5.61 6.37
EPS Growth Rate
(3Y to 5Y Estimate)
7.26%
Dividends Per Share ($)
» More Articles for NAS:MYL

Headlines

Articles On GuruFocus.com
10 Biotech and Specialty Pharma Bargains: Do You Have the Guts to Speculate? Jul 01 2016 
Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
Samuel Isaly Trades in Health Care Stocks in 1st Quarter Apr 27 2016 
John Keeley Comments on Mylan Labs Apr 26 2016 
Ackman to Testify About Valeant Before Senate Apr 26 2016 
Mawer's Investment Newsletter 1st Quarter Apr 15 2016 
Insiders Keep on Selling Facebook and Ford Apr 08 2016 
Buy Perrigo After a Big Selloff? Yes Apr 04 2016 
David Einhorn's Top 5 New Q4 Buys Feb 16 2016 
David Einhorn Rebounds – Somewhat Feb 09 2016 

More From Other Websites
Zacks.com featured highlights: Korea Electric Power, Third Point Reinsurance, Mylan N.V. and Gray... Jul 28 2016
FTC give go-ahead for Mylan’s $7.2 billion purchase of Meda Jul 27 2016
Mylan Receives U.S. FTC Clearance for Proposed Meda Acquisition Jul 27 2016
4 Buy-Rated Stocks with High Earnings Yield Jul 27 2016
Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say Jul 26 2016
Why these traders are buying puts in Mylan Jul 26 2016
Mylan’s EpiPen price increases are Valeant-like in size, Shkreli-like in approach Jul 23 2016
EU watchdog flags faulty generic drug data, backs sales halt Jul 22 2016
Mylan Publishes Supplement to Meda Offer Document Jul 21 2016
Mylan And Biocon Says EMA Accept Its Regulatory Submission Of Biosimilar Pegfilgrastim Jul 21 2016
Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for... Jul 21 2016
[$$] Business Watch Jul 20 2016
Mylan Gets EC Clearance for Meda Purchase Jul 20 2016
Mylan Launches Generic Crestor® Tablets Jul 20 2016
Mylan gets EU approval for Meda purchase, subject to conditions Jul 20 2016
Mylan gets EU approval for Meda purchase, subject to conditions Jul 20 2016
Mylan Is Poised to Break Sideways Trend Jul 19 2016
The Zacks Analyst Blog Highlights: Manulife Financial, Mylan, Huntsman, Air Lease and Bofi Holding Jul 18 2016
6 Stocks Still Trading Cheap in Today's Market Jul 15 2016
Exclusive - Mylan to get EU green light for Swedish drugmaker deal: sources Jul 15 2016
These Four Drugs Were Withdrawn by the CHMP in June Jul 12 2016
UBS Quality Growth at a Reasonable Price Stocks Crush the S&P 500: 3 to Buy Right Now Jul 12 2016
Mylan Unveils Generic Temodar Capsules Jul 11 2016
Mylan Launches Generic Temodar® Capsules Jul 11 2016
In fight for GSK's Advair, generic firms step carefully on price Jun 03 2016
In fight for GSK's Advair, generic firms step carefully on price Jun 03 2016
EU regulators to rule on Mylan's $7.2 billion Meda bid by July 6 Jun 02 2016
Mylan tops 1Q profit forecasts May 03 2016
Mylan to present at Meda’s Annual General Meeting Apr 07 2016
Drugmaker Perrigo expects $100 million boost from new Israeli plant Mar 02 2016
Business Highlights Feb 10 2016
Mylan offers to buy Swedish pharma firm Meda for $9.9 bn Feb 10 2016
Mylan to buy Sweden's Meda AB for $7.2 billion Feb 10 2016
Mylan misses Street 4Q forecasts Feb 10 2016
Mylan offers to buy Swedish pharma firm Meda for $9.9 bn Feb 10 2016
U.S. copy of GSK's Advair a step closer as Mylan files generic version Jan 12 2016
2016 Jan 06 Phosphagenics Initiates Arbitration Against Mylan Jan 06 2016
Phosphagenics Initiates Arbitration against Mylan Jan 06 2016
Mylan Appoints Ranjan Ray Chaudhuri as Global Commercial Lead for Mylan's Over-the-Counter Business Nov 24 2015
Mylan Third Quarter 2015 Constant Currency Adjusted Total Revenues Increase 36% and Adjusted Diluted... Nov 23 2015
U.S. District Court Denies Perrigo's Motion for Preliminary Injunction Related to Certain Mylan... Nov 20 2015
Mylan Confirms Availability of EpiPen® (epinephrine injection) Auto-Injector for U.S. Patients... Nov 19 2015
Tel Aviv District Court Rules in Favor of Mylan Listing on Tel Aviv Stock Exchange Nov 19 2015
US STOCKS-U.S. stocks fall, with retail, technology leading rout Nov 13 2015
Big deal momentum may carry into 2016 for health care Nov 13 2015
Mylan's $35 bn bid for Perrigo fails Nov 13 2015
Perrigo to go it alone; shareholders reject $26B Mylan bid Nov 13 2015
Perrigo tumbles as shareholders reject Mylan offer Nov 13 2015
Shareholders of drugmaker Perrigo shut the door on Mylan and its $26B, hostile takeover bid Nov 13 2015
Mylan's $35 bn bid for Perrigo fails Nov 13 2015
Mylan's tender offer for Perrigo unlikely to succeed - sources Nov 12 2015
Mylan-targeted Perrigo held merger talks with Endo - sources Nov 12 2015
Perrigo Reaffirms Views on Mylan's Inadequate Offer; Maintains Strong Recommendation Shareholders... Nov 10 2015
Perrigo Issues Shareholder Letter Nov 09 2015
Cabinet okays $750 mn investment by Dutch drug major Nov 05 2015
Mylan not relying on acquisitions if Perrigo bid fails -chairman Nov 04 2015
FTC approves Mylan's hostile bid for Perrigo with conditions Nov 03 2015
FTC clears Mylan's $27B proposed takeover of Perrigo Nov 03 2015
FTC approves Mylan's hostile bid for Perrigo with conditions Nov 03 2015
FTC approves hostile Mylan takeover of Perrigo with conditions Nov 03 2015
Perrigo Comments On Mylan's Presentation Oct 30 2015
Mylan profit beats as generic sales jump in North America and Europe Oct 30 2015
Mylan beats 3Q profit forecasts Oct 30 2015
U.S. FDA warns Novartis on manufacturing violations at two India plants Oct 28 2015
Perrigo CEO doesn't believe Mylan's hostile bid will succeed Oct 27 2015
Perrigo Taking Actions To Deliver Shareholder Value Far Superior To Mylan Offer Oct 22 2015
Paragraph IV Notice from Mylan Technologies Inc... Oct 05 2015
Perrigo Board Unanimously Rejects Mylan's Unsolicited Exchange Offer As Inadequate Sep 17 2015
Mylan takes takeover bid to Perrigo shareholders Sep 14 2015
Mylan Statement in Response to FDA Warning Letter Relating to Certain Agila Facilities Sep 14 2015
Perrigo Announcement Regarding Unsolicited Offer From Mylan N.V. Sep 14 2015
Theravance Biopharma and Mylan Initiate Phase 3 Program for Revefenacin (TD-4208) for Treatment of... Sep 14 2015
Perrigo Responds to Misleading Letter from Mylan Executive Chairman Sep 10 2015
Mylan takes takeover bid to Perrigo shareholders Sep 08 2015
Mylan shareholders approve hostile takeover Aug 28 2015
Mylan gets EU clearance for Perrigo clearance Jul 29 2015
Hikma to buy Boehringer's U.S. generic drug business for $2.65 bln Jul 28 2015
Teva to buy Allergan generic business for $40.5 bln, drops Mylan bid Jul 27 2015
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid Jul 27 2015
Teva to buy Allergan generic drug unit for $40.5 bn Jul 27 2015
Mylan foundation to block Israel's Teva hostile takeover bid Jul 23 2015
Teva to lift bid for Mylan: report Jul 06 2015
Exclusive - Teva poised to raise its stake in Mylan -sources Jun 02 2015
Endo pushes further into generics with $8 bln Par Pharma buy May 18 2015
Big pharma deals: Mylan raises bid for Perrigo to $35.6 bn Apr 30 2015
Generic drugmaker Teva makes $40 billion offer for rival Mylan Apr 21 2015
Top Mylan shareholders seek deal with Teva - sources Apr 21 2015
Exclusive - Perrigo expected to reject Mylan offer as soon as this week: source Apr 21 2015
Mylan settles Viagra patent litigation with Pfizer Apr 13 2015
Generic drugmaker Mylan offers $29 billion for Perrigo Apr 08 2015
Corrected - UK says Mylan recalls batches of Polish-made antibiotic Jun 19 2014
UK says Mylan recalls batches of Indian-made antibiotic Jun 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)